J90.F NUREXONE BIOLOGIC INC.
- Market cap
- EUR 25.9M
- P/E
- -
- P/B
- 24.15x
- ROE
- -544.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is J90.F undervalued?
Graham numberThe Graham number of NUREXONE BIOLOGIC INC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NUREXONE BIOLOGIC INC. fundamental analysis
No fundamental analysis for NUREXONE BIOLOGIC INC. yet.
NUREXONE BIOLOGIC INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.
Full company profileNUREXONE BIOLOGIC INC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NUREXONE BIOLOGIC INC. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.71M | -5.54M | -3.66M | -5.01M | -6.32M | -6.86M |
| EBITDA | - | -8.12M | -3.60M | -4.94M | -6.17M | -6.61M |
| Net Income | -1.65M | -8.17M | -3.64M | -5.04M | -6.38M | -6.90M |
| EPS | -0.04 | -0.19 | -0.08 | -0.07 | -0.07 | -0.07 |
| Balance Sheet | ||||||
| Total Assets | 2.84M | 2.79M | 2.17M | 2.44M | 4.08M | 2.62M |
| Total Liabilities | 1.66M | 698K | 1.98M | 680K | 1.33M | 1.35M |
| Shareholders' Equity | 1.18M | 2.10M | 189K | 1.76M | 2.76M | 1.27M |
| Cash & Short-term Investments | 2.21M | 2.46M | 541K | 700K | 2.14M | 1.01M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.23M | -3.85M | -2.94M | -4.89M | -4.51M | -4.38M |
| Capital Expenditure | 0.00 | 52.0K | 120K | 649K | 55.0K | 72.0K |
| Free Cash Flow | -1.23M | -3.90M | -3.06M | -5.54M | -4.57M | -4.46M |
| Ratios | ||||||
| ROE | -139.9% | -389.7% | -1,925.4% | -286.4% | -231.5% | -544.9% |
| ROA | -58.1% | -292.4% | -167.7% | -206.6% | -156.4% | -263.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
NUREXONE BIOLOGIC INC. dividends
NUREXONE BIOLOGIC INC. has not paid dividends in the last 5 fiscal years.
Who owns NUREXONE BIOLOGIC INC.
- Insiders 6.24%
- Institutions 0.00%
- Public & others 93.76%
- Shares outstanding 92.0M
- Free float 91.9M
NUREXONE BIOLOGIC INC. company profile
- Company name
- NUREXONE BIOLOGIC INC.
- Ticker
- J90.F
- ISIN
- CA67059R1091
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9
- Website
- nurexone.com
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.
NUREXONE BIOLOGIC INC. management
10- Mr. Yoram DruckerCo-Founder, VP of Strategic Development & Chairman · born 1965
- Dr. Lior Shaltiel Ph.D.CEO & Director
- Mr. Eran Ovadya M.B.A.CFO, Financial Director & Secretary · born 1983
- Mr. Gabriel EldorCo-Founder & Business Development Manager
- Prof. Shulamit Levenberg Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1963
- Dr. Daniel Offen Ph.D.Co-Founder
- Dr. Ram Petter M.B.A., Ph.D.Head of Operations
- Dr. Tali Kizhner Ph.D.Director of Research & Development
- Prof. Nahshon Knoller M.D.Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board
- Dr. Ina Sarel Ph.D.Head of CMC, Quality & Regulation